News & Updates

In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.

In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).

Baseline health-related quality of life (HRQOL) among patients with localized high-risk prostate cancer prior to radical prostatectomy is an important and a strong predictor of survival, suggests a study.

Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.

In the treatment of patients with ICI-naïve nonsmall cell lung cancer (NSCLC), adding the cytotoxic chemotherapy docetaxel to the immune-checkpoint inhibitor (ICI) nivolumab leads to a significantly longer survival, although at the expense of slightly elevated toxicity, according to the results of a phase II/III trial.

Adjuvant pembrolizumab significantly improves disease-free survival (DFS) vs placebo in patients with completely resected, PD-L1–unselected, stage IB–IIIA non-small-cell lung cancer (NSCLC), a second interim analysis of the triple-blind phase III PEARLS/KEYNOTE-091 trial has shown.

In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.